Cathie Wood's ARK sells AMD stock, buys SpaceX and X-Energy By Investing.com

Cathie Wood's ARK ETF published their daily trades for Tuesday, July 7th, 2026, shedding light on significant moves across its portfolio. The most notable transaction was the purchase of 607,567 shares of X-Energy Inc (NASDAQ:XE) through its ARKK ETF, ARKQ ETF, and ARKX ETF, totaling $11,130,627. This continues a trend from previous days, showing ARK's growing interest in X-Energy.

In a substantial sell, ARK offloaded 8,667 shares of Advanced Micro Devices Inc (NASDAQ:AMD) through its ARKK ETF, amounting to $4,784,617. This sale follows a pattern, as ARK sold 15,576 shares of AMD the previous day, indicating a potential shift in strategy regarding this stock.

ARK also made a significant purchase of 44,196 shares of Space Exploration Technologies Corp (SPCX) through its ARKK ETF, with a total value of $7,089,922. This marks a considerable addition to their holdings, emphasizing ARK's bullish stance on SpaceX.

Another notable buy was 6,354 shares of Eli Lilly and Co (NYSE:LLY) via the ARKG ETF, valued at $7,625,181, highlighting ARK's interest in the pharmaceutical sector.

On the selling front, ARK divested 44,330 shares of BioNTech SE (NASDAQ:BNTX) from its ARKG ETF, totaling $4,163,916. This follows a broader trend of reducing positions in biotech firms.

ARK's ARKG ETF also saw the sale of 72,323 shares of Adaptive Biotechnologies Corp (NASDAQ:ADPT), valued at $1,554,944, and 39,151 shares of CareDx Inc (NASDAQ:CDNA), worth $1,137,728, further reflecting a strategic shift in the biotech space.

Meanwhile, ARK increased its stake in Compass Pathways PLC (NASDAQ:CMPS) by acquiring 191,070 shares through the ARKG ETF, amounting to $2,453,338, suggesting confidence in the potential of mental health therapeutics.

Additionally, ARK continued to invest in Generate Biomedicines Inc (GENB) with the purchase of 44,170 shares through the ARKG ETF, valued at $747,356, following previous buys in recent days.

Finally, ARK sold 40,787 shares of Illumina Inc (NASDAQ:ILMN) across its ARKK and ARKG ETFs, and 20,992 shares of Natera Inc (NASDAQ:NTRA), totaling $5,957,529, showing a consistent pattern of reducing exposure to these genomics companies.

These trades illustrate ARK's dynamic investment strategy, balancing between high-conviction buys and strategic sales to optimize its portfolio in the ever-evolving market landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.